Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Infection

Antimicrob Agents Chemother. 2017 Sep 22;61(10):e01265-17. doi: 10.1128/AAC.01265-17. Print 2017 Oct.

Abstract

There are limited therapeutic options to treat infections caused by vancomycin-resistant Enterococcus faecium (VREfm). The lipoglycopeptide oritavancin exhibits in vitro activity against this pathogen, although its utility against infections caused by VREfm has not been clinically established. In this study, the pharmacodynamic activity of free-drug levels associated with 12 mg/kg/day of daptomycin and a single 1,200-mg dose of oritavancin were determined against three VanA VREfm isolates in an in vitro pharmacokinetic/pharmacodynamic model.

Keywords: Enterococcus faecium; daptomycin; lipoglycopeptide; oritavancin; vancomycin resistance.

MeSH terms

  • Anti-Bacterial Agents / pharmacokinetics
  • Anti-Bacterial Agents / pharmacology*
  • Daptomycin / pharmacokinetics
  • Daptomycin / pharmacology
  • Enterococcus faecium / drug effects*
  • Enterococcus faecium / isolation & purification
  • Glycopeptides / pharmacokinetics*
  • Glycopeptides / pharmacology*
  • Gram-Positive Bacterial Infections / drug therapy*
  • Humans
  • Lipoglycopeptides
  • Microbial Sensitivity Tests
  • Vancomycin Resistance / physiology
  • Vancomycin-Resistant Enterococci / drug effects*
  • Vancomycin-Resistant Enterococci / isolation & purification

Substances

  • Anti-Bacterial Agents
  • Glycopeptides
  • Lipoglycopeptides
  • Daptomycin
  • oritavancin